Avalik loeng "Bioengineering Transplantable Organs and related IP developments"
- Koht: SOC 209
Kolmapäeval, 24. aprillil kell 14 - 15 toimub ruumis SOC 209 avalik loeng teemal "Bioengineering Transplantable Organs and related IP developments".
Kokkuvõte inglise keeles
Tallinn Law School of Tallinn University of Technology (TalTech) is pleased to announce that Dr. Jeff Ross, CEO of Miromatrix will be visiting Tallinn to deliver a public lecture on the topic of "Bioengineering Transplantable Organs and related IP developments." The above lecture is being organized with the help of the US Consulate.
Dr. Ross brings more than 20 years of biomedical research, management and regulatory experience in regenerative medicine, biologics, and medical devices to Miromatrix including concept development, preclinical, clinical, manufacturing, and commercialization. He has held various technical and management positions at Guidant, Athersys and SurModics. Since coming to Miromatrix in 2010 he has been pivotal in the development, manufacturing and regulatory clearance of the innovative MIROMESH and MIRODERM product lines. He has spearheaded development, global patent strategy, and fundraising for the revolutionary whole organ transplant program and its key decellularization technology. Dr. Ross has over 30 patents along with scientific publications in Nature and other peer reviewed journals. He holds a Master’s degree in Biomedical Engineering and a Ph.D. in Molecular, Cellular and Developmental Biology from the University of Minnesota.